In 2013 Subsys was the most widely prescribed branded opioid in its class (transmucosal immediate-release fentanyl) and that same year Insys Pharma. became the best-performing IPO. All the while, federal agencies were pursuing criminal investigations. https://www.nytimes.com/interactive/2018/05/02/magazine/money-issue-insys-opioids-kickbacks.html …

In 2013 Subsys was the most widely prescribed branded opioid in its class (transmucosal immediate-release fentanyl) and that same year Insys Pharma. became the best-performing IPO. All the while, federal agencies were pursuing criminal investigations. https://www.nytimes.com/interactive/2018/05/02/magazine/money-issue-insys-opioids-kickbacks.html …

source https://twitter.com/ASAMorg/status/996726985157218304